Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

Related Keywords

United States ,Russia ,Ukraine ,Ashleyr Robinson ,Robert Ferrara ,Robert Bitterman ,Isolagen Inc ,Biofrontera Inc ,Boston University ,York College Of Podiatric Medicine ,Phio Pharmaceuticals Corp ,Nasdaq ,Master Of Business Administration ,Phio Pharmaceuticals ,Company Board ,Cutanea Life Sciences Inc ,College Of The Holy Cross ,Prnewswire Phio Pharmaceuticals Corp ,Chief Executive Officer ,Interim Chief Executive Officer ,Lead Independent ,Interim Executive Chairman ,Cutanea Life Sciences ,General Manager ,Dermik Laboratories ,Holy Cross ,Business Administration ,Humane Letters ,Honoris Causa ,New York College ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,